GlassScriptPhysician profile
Bryce Frederick Schutte
NPI 1588235287
$2,159.78
in general payments reported to CMS, 2019-2025
23 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.97 · 2022: $136 · 2023: $15.77 · 2024: $359 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.46 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $707.86 | 2024-2025 | Fasenra, Airsupra, Breztri |
| United Therapeutics Corporation | $253.71 | 2022-2025 | Tyvaso |
| Insmed, INC. | $136.61 | 2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.09 | 2021-2025 | Ofev, Jascayd |
| Becton, Dickinson and Company | $109.32 | 2025 | Hemosphere |
| Jazz Pharmaceuticals INC. | $107.35 | 2025 | |
| Merck Sharp & Dohme LLC | $98.13 | 2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $78.14 | 2022-2025 | Dupixent |
| Genzyme Corporation | $71.89 | 2022-2025 | |
| Grifols USA, LLC | $71.33 | 2024-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $68.04 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $56.10 | 2024-2025 | Lumryz |
| Viatris Specialty LLC | $46.97 | 2025 | Yupelri |
| Amgen INC. | $34.80 | 2024 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $32.99 | 2024-2025 | Uptravi, Opsynvi, Opsumit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $24.82 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.36 | 2025 | Glassia |
| Baxter Healthcare | $22.95 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $19.18 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.54 | 2022 | |
| Glaxosmithkline, LLC. | $15.96 | 2025 | Nucala |
| Sobi, INC | $15.77 | 2023 | |
| Lilly USA, LLC | $14.87 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Schutte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.